These results confirmed that EcN/PCSK9nb engineered bacteria could alleviate the development of atherosclerosis by protecting LDLR, substantially reducing serum LDL‐C levels and hepatic lipid accumulation, and reducing inflammation. The gene discussed is LDLR; the disease is atherosclerosis.